Chemotherapy Induced Nausea and Vomiting (CINV):
- Chemotherapy-induced nausea and vomiting is a common and distressing side effect of cancer treatment.
- Antiemetic drugs are used to prevent and control CINV in cancer patients.
- These drugs work by blocking specific receptors in the brain that trigger the sensations of nausea and vomiting.
- The introduction of novel antiemetic drugs and the increasing adoption of combination therapies are driving the growth of the CINV segment in the cancer supportive care drugs market.
- Factors such as the rising incidence of chemotherapy treatments and the growing focus on improving the quality of life for cancer patients are expected to further propel the demand for CINV drugs.
- The cancer supportive care drugs market is highly competitive, with several key players operating globally.
- Major pharmaceutical companies are focusing on strategic collaborations, mergers and acquisitions, and product innovations to strengthen their market position.
- Some of the prominent players in the market include Amgen Inc., Pfizer Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Novartis AG, and Johnson & Johnson Services, Inc.
- These companies are investing heavily in R&D activities to develop advanced cancer supportive care drugs and expand their product portfolios.
- Moreover, market players are also focusing on geographic expansion and partnerships with healthcare facilities to enhance their distribution networks.